What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue ...

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

American hospitals and utilities are on alert for the possibility of cyberattacks following the US airstrikes on Iranian ...

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...